Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2,Double-Blind, Randomized, Placebo-Controlled, Dose Escalating, Multicenter Study of SGX942 For the Attenuation of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

NCT02013050 is registered in ClinicalTrials.gov with Soligenix as lead sponsor.

NCT NCT02013050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02013050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2,Double-Blind, Randomized, Placebo-Controlled, Dose Escalating, Multicenter Study of SGX942 For the Attenuation of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Soligenix
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2013
Completion date
September 30, 2016
Enrollment
111 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oral mucositis